Clinical trial
Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand…
NCT00124475 · Basilea Pharmaceutica, Industry · Completed
Key facts
| NCT number | NCT00124475 |
|---|---|
| Title | Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis |
| Official title | Efficacy and Safety of BAL4079 in the Treatment of Severe Refractory Chronic Hand Dermatitis |
| Lead sponsor | Basilea Pharmaceutica, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hand Dermatoses |
| Intervention type | Drug |
| Interventions | alitretinoin |
| Enrollment | 1,035 |
| Start date | Dec 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Jul 28, 2005 |
| Last update posted | May 10, 2023 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: